In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition

Aixa Rodríguez, Kyle Kleinbeck, Olga Mizenina, Larisa Kizima, Keith Levendosky, Ninochka Jean-Pierre, Guillermo Villegas, Brian E. Ford, Michael L. Cooney, Natalia Teleshova, Melissa Robbiani, Betsy Herold, Thomas Zydowsky, José A. Fernández Romero

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy, dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect of seminal plasma (SP). The Population Council's PC-515 gel and the lubricant Divine 9 were tested for their physicochemical properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations were applied intravaginally either 2 h pre/2 h post (-2 h/+2 h) or 24 h pre (-24 h) relative to challenge with HPV16 or 45 PsV in PBS or SP/PBS. Both formulations showed broad-spectrum anti-HPV activity in vitro (IC 50: 1-20 ng/ml), significantly decreasing HPV PsV infection in the mouse model (-2 h/+2 h, p < 0.0001). PC-515 protected better than Divine 9 in the -24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the -2 h/+2 h regimen (p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.

Original languageEnglish (US)
Pages (from-to)88-93
Number of pages6
JournalAntiviral Research
Volume108
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Carrageenan
Semen
Human Activities
Papillomavirus Infections
Luciferases
Lubricants
Papillomavirus Vaccines
Refrigeration
HeLa Cells
Gels
In Vitro Techniques
Costs and Cost Analysis
Population

Keywords

  • HPV
  • Microbicides
  • STI

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Rodríguez, A., Kleinbeck, K., Mizenina, O., Kizima, L., Levendosky, K., Jean-Pierre, N., ... Fernández Romero, J. A. (2014). In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. Antiviral Research, 108(1), 88-93. https://doi.org/10.1016/j.antiviral.2014.05.018

In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. / Rodríguez, Aixa; Kleinbeck, Kyle; Mizenina, Olga; Kizima, Larisa; Levendosky, Keith; Jean-Pierre, Ninochka; Villegas, Guillermo; Ford, Brian E.; Cooney, Michael L.; Teleshova, Natalia; Robbiani, Melissa; Herold, Betsy; Zydowsky, Thomas; Fernández Romero, José A.

In: Antiviral Research, Vol. 108, No. 1, 2014, p. 88-93.

Research output: Contribution to journalArticle

Rodríguez, A, Kleinbeck, K, Mizenina, O, Kizima, L, Levendosky, K, Jean-Pierre, N, Villegas, G, Ford, BE, Cooney, ML, Teleshova, N, Robbiani, M, Herold, B, Zydowsky, T & Fernández Romero, JA 2014, 'In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition', Antiviral Research, vol. 108, no. 1, pp. 88-93. https://doi.org/10.1016/j.antiviral.2014.05.018
Rodríguez, Aixa ; Kleinbeck, Kyle ; Mizenina, Olga ; Kizima, Larisa ; Levendosky, Keith ; Jean-Pierre, Ninochka ; Villegas, Guillermo ; Ford, Brian E. ; Cooney, Michael L. ; Teleshova, Natalia ; Robbiani, Melissa ; Herold, Betsy ; Zydowsky, Thomas ; Fernández Romero, José A. / In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. In: Antiviral Research. 2014 ; Vol. 108, No. 1. pp. 88-93.
@article{397509c85c0a48c991f18831fc834593,
title = "In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition",
abstract = "Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy, dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect of seminal plasma (SP). The Population Council's PC-515 gel and the lubricant Divine 9 were tested for their physicochemical properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations were applied intravaginally either 2 h pre/2 h post (-2 h/+2 h) or 24 h pre (-24 h) relative to challenge with HPV16 or 45 PsV in PBS or SP/PBS. Both formulations showed broad-spectrum anti-HPV activity in vitro (IC 50: 1-20 ng/ml), significantly decreasing HPV PsV infection in the mouse model (-2 h/+2 h, p < 0.0001). PC-515 protected better than Divine 9 in the -24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the -2 h/+2 h regimen (p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.",
keywords = "HPV, Microbicides, STI",
author = "Aixa Rodr{\'i}guez and Kyle Kleinbeck and Olga Mizenina and Larisa Kizima and Keith Levendosky and Ninochka Jean-Pierre and Guillermo Villegas and Ford, {Brian E.} and Cooney, {Michael L.} and Natalia Teleshova and Melissa Robbiani and Betsy Herold and Thomas Zydowsky and {Fern{\'a}ndez Romero}, {Jos{\'e} A.}",
year = "2014",
doi = "10.1016/j.antiviral.2014.05.018",
language = "English (US)",
volume = "108",
pages = "88--93",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition

AU - Rodríguez, Aixa

AU - Kleinbeck, Kyle

AU - Mizenina, Olga

AU - Kizima, Larisa

AU - Levendosky, Keith

AU - Jean-Pierre, Ninochka

AU - Villegas, Guillermo

AU - Ford, Brian E.

AU - Cooney, Michael L.

AU - Teleshova, Natalia

AU - Robbiani, Melissa

AU - Herold, Betsy

AU - Zydowsky, Thomas

AU - Fernández Romero, José A.

PY - 2014

Y1 - 2014

N2 - Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy, dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect of seminal plasma (SP). The Population Council's PC-515 gel and the lubricant Divine 9 were tested for their physicochemical properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations were applied intravaginally either 2 h pre/2 h post (-2 h/+2 h) or 24 h pre (-24 h) relative to challenge with HPV16 or 45 PsV in PBS or SP/PBS. Both formulations showed broad-spectrum anti-HPV activity in vitro (IC 50: 1-20 ng/ml), significantly decreasing HPV PsV infection in the mouse model (-2 h/+2 h, p < 0.0001). PC-515 protected better than Divine 9 in the -24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the -2 h/+2 h regimen (p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.

AB - Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy, dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect of seminal plasma (SP). The Population Council's PC-515 gel and the lubricant Divine 9 were tested for their physicochemical properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations were applied intravaginally either 2 h pre/2 h post (-2 h/+2 h) or 24 h pre (-24 h) relative to challenge with HPV16 or 45 PsV in PBS or SP/PBS. Both formulations showed broad-spectrum anti-HPV activity in vitro (IC 50: 1-20 ng/ml), significantly decreasing HPV PsV infection in the mouse model (-2 h/+2 h, p < 0.0001). PC-515 protected better than Divine 9 in the -24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the -2 h/+2 h regimen (p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.

KW - HPV

KW - Microbicides

KW - STI

UR - http://www.scopus.com/inward/record.url?scp=84903218843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903218843&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2014.05.018

DO - 10.1016/j.antiviral.2014.05.018

M3 - Article

C2 - 24909570

AN - SCOPUS:84903218843

VL - 108

SP - 88

EP - 93

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -